Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…Abstract Number: LB09 • ACR Convergence 2025
Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is initially treated with non-steroidal anti-inflammatory drugs. In case of inadequate response, ACR/EULAR recommend biological disease-modifying antirheumatic drugs (bDMARDs). Up to…Abstract Number: LB11 • ACR Convergence 2025
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease whose pathogenesis is associated with aberrant activation of B-lymphocytes. Telitacicept, a novel fusion protein, dually targets and…Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…Abstract Number: 2610 • ACR Convergence 2025
Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy
Background/Purpose: Aortitis is a frequent and potential severe complication of giant cell arteritis (GCA)(GCA-aortitis). Tocilizumab (TCZ) was approved for the treatment of GCA, but its…Abstract Number: 2450 • ACR Convergence 2025
Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
Background/Purpose: Anifrolumab is a biologic recently approved for systemic lupus erythematosus (SLE), with efficacy shown in trials, but data from real-world practice remain limited. The…Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…Abstract Number: 1921 • ACR Convergence 2025
Re-escalation of Treatment in Older Adults with Rheumatoid Arthritis After Anti-TNF Therapy De-escalation
Background/Purpose: Older adults with rheumatoid arthritis (RA) treated with biologic disease-modifying antirheumatic drugs (bDMARDs), including anti-TNFs, are at an increased risk of adverse effects. Current…Abstract Number: 1545 • ACR Convergence 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…Abstract Number: 1439 • ACR Convergence 2025
Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Background/Purpose: Bimekizumab, a dual IL-17 A and F blocker, has recently been added in the therapeutic rheumatologist’s armamentarium of PsA, but real-world evidence is lacking.…Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…Abstract Number: 1055 • ACR Convergence 2025
The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
Background/Purpose: High-cost biologic therapies are integral to the management of rheumatoid arthritis (RA), yet access to these agents may be influenced by insurance type, particularly…Abstract Number: 0574 • ACR Convergence 2025
Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Background/Purpose: Psoriatic arthritis (PsA) affects up to one-third of patients with psoriasis;1 early identification and intervention for patients with psoriasis and risk factors (RFs) for…Abstract Number: 0780 • ACR Convergence 2025
Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by IFNg-driven macrophage activation and systemic hyperinflammation. Chemokine C-X-C motif ligand 9 (CXCL9) is released…Abstract Number: 0475 • ACR Convergence 2025
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Background/Purpose: In April 2022, the Canadian province of Quebec introduced a mandatory non-medical switch to biosimilars for persons on bio-originators to manage healthcare costs. Our…
- 1
- 2
- 3
- …
- 67
- Next Page »